These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1416032)

  • 1. Gas chromatography/mass spectrometry assays for the determination of debrisoquine and sparteine metabolites in microsomal fractions of rat liver.
    Ho JW; Moody DE
    Anal Biochem; 1992 Jun; 203(2):348-51. PubMed ID: 1416032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.
    Ebner T; Eichelbaum M
    Br J Clin Pharmacol; 1993 Apr; 35(4):426-30. PubMed ID: 8485023
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver.
    Osikowska-Evers BA; Eichelbaum M
    Life Sci; 1986 May; 38(19):1775-82. PubMed ID: 3702606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol.
    Gut J; Catin T; Dayer P; Kronbach T; Zanger U; Meyer UA
    J Biol Chem; 1986 Sep; 261(25):11734-43. PubMed ID: 3745165
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
    Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
    Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
    Otton SV; Brinn RU; Gram LF
    Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
    Dayer P; Kronbach T; Eichelbaum M; Meyer UA
    Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.
    Fonne-Pfister R; Meyer UA
    Biochem Pharmacol; 1988 Oct; 37(20):3829-35. PubMed ID: 2903741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereo- and regioselectivity of hepatic oxidation in man--effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.
    Dayer P; Leemann T; Küpfer A; Kronbach T; Meyer UA
    Eur J Clin Pharmacol; 1986; 31(3):313-8. PubMed ID: 2878813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians.
    Lennard MS; Iyun AO; Jackson PR; Tucker GT; Woods HF
    Pharmacogenetics; 1992 Apr; 2(2):89-92. PubMed ID: 1302046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.
    Broly F; Vandamme N; Libersa C; Lhermitte M
    Br J Clin Pharmacol; 1991 Oct; 32(4):459-66. PubMed ID: 1958440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine.
    Otton SV; Inaba T; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1982 Jan; 60(1):102-5. PubMed ID: 7066751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A human cytochrome P-450 characterized by inhibition studies as the sparteine-debrisoquine monooxygenase.
    Inaba T; Nakano M; Otton SV; Mahon WA; Kalow W
    Can J Physiol Pharmacol; 1984 Jul; 62(7):860-2. PubMed ID: 6498616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes.
    Otton SV; Crewe HK; Lennard MS; Tucker GT; Woods HF
    J Pharmacol Exp Ther; 1988 Oct; 247(1):242-7. PubMed ID: 3171974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 3,4-Dehydrodebrisoquine, a novel debrisoquine metabolite formed from 4-hydroxydebrisoquine that affects the CYP2D6 metabolic ratio.
    Zhen Y; Slanar O; Krausz KW; Chen C; Slavík J; McPhail KL; Zabriskie TM; Perlík F; Gonzalez FJ; Idle JR
    Drug Metab Dispos; 2006 Sep; 34(9):1563-74. PubMed ID: 16782768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectral binding studies of the polymorphically metabolized drugs debrisoquine, sparteine and phenformin by cytochrome P-450 of normal and hydroxylation deficient rat strains.
    Küpfer A; Al-Dabbagh SG; Ritchie JC; Idle JR; Smith RL
    Biochem Pharmacol; 1982 Oct; 31(20):3193-9. PubMed ID: 7150348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
    Woolhouse NM
    Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with type II autoimmune hepatitis express functionally intact cytochrome P-450 db1 that is inhibited by LKM-1 autoantibodies in vitro but not in vivo.
    Manns M; Zanger U; Gerken G; Sullivan KF; Meyer zum Büschenfelde KH; Meyer UA; Eichelbaum M
    Hepatology; 1990 Jul; 12(1):127-32. PubMed ID: 2373473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Debrisoquine/sparteine-type polymorphic drug metabolism in wild Clethrionomys rufocanus.
    Hoshi H; Masuda M; Yamamoto Y; Suimamoto Y; Kazusaka A; Fujita S
    Drug Metab Dispos; 1995 Nov; 23(11):1301-3. PubMed ID: 8591735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.